AI-powered therapy-gap detection across the full cardiovascular continuum. Surfaces missed diagnoses, delayed referrals, and underutilized therapies at scale.
Despite proven guideline-directed therapies, cardiovascular patients remain dramatically undertreated. TAILRD translates these gaps into prioritized, system-level opportunities.
Most cardiac AI tools solve a narrow problem. TAILRD was built to see the entire system.
Unlike point solutions, TAILRD analyzes the entire cardiovascular journey - from early risk identification to advanced intervention - continuously, not episodically.
TAILRD doesn't just identify disease. It flags patients who should already be receiving care - but aren't.
Co-developed with Mount Sinai — U.S. News & World Report #2 cardiac hospital in the U.S.
Every insight is anchored in guidelines, real-world data, and validated clinical pathways - not black-box predictions.
Insights route to the right stakeholder - clinicians, service line leaders, and executives - in formats designed for action, not dashboards.
Multi-module, multi-service-line architecture that expands with your cardiovascular program - from pilots to system-wide deployment.
TAILRD continuously scans every stage of the cardiovascular continuum - not just the moment of intervention. From early risk signals to late-stage procedures, therapy gaps emerge long before patients reach specialty care. TAILRD identifies those gaps early - and keeps tracking them until care is delivered.
Actionable intelligence from system-wide visibility down to individual patient recommendations-designed to drive execution in real workflows.
Each module is built as an offering: it identifies therapy gaps, flags missed interventions, and routes actionable worklists to the right teams.
Surfaces untreated and undertreated HF patients across primary and specialty care - before decompensation occurs.
Identifies rhythm patients who meet criteria for anticoagulation, monitoring, or intervention - but haven't received it.
Flags echo findings, referral gaps, and delayed interventions across the structural disease spectrum.
Detects missed opportunities in CAD risk stratification, diagnosis, and escalation of care.
Surfaces progressive valve disease earlier - when intervention can still change outcomes.
Expands PAD detection, closes medical therapy gaps, identifies revascularization and limb-preservation candidates, and coordinates longitudinal pathways.
Validated through collaborations, pilots, and co-development with leading health systems and research organizations.
TAILRD also supports med device and pharma partners seeking real-world cardiovascular intelligence-delivered through trusted health system workflows.
Cardiovascular operators and builders with deep clinical, technical, and health-system experience.
TAILRD reveals where care breaks down - clinically and operationally - and gives your teams the insight to fix it.